Generate QR code
Open Access
Subscription Access
Russian pharmaceutical companies: Business models of market leaders
https://doi.org/10.32609/0042-8736-2019-8-127-138
Abstract
Many factors influence firms’ growth possibilities and market positions. This paper deals with business models as company’s competitiveness determinant; the case of Russian leading pharmaceutical companies is studied. The review of global pharmaceutical leaders’ business models is presented. Russian leaders are indentified basing on empirical data provided by SPARK database. It has been found that they use models of disruptive research, models aimed at business value growth as well as models of active portfolio management. Characteristics and perspectives of each model type are determined.
About the Authors
Nataliya A. Kravchenko
Institute of Economics and Industrial Engineering, Siberian Branch of the Russian Academy of Sciences; Novosibirsk State University
Russian Federation
Russian Federation
Novosibirsk
Almira T. Yusupova
Institute of Economics and Industrial Engineering, Siberian Branch of the Russian Academy of Sciences; Novosibirsk State University
Russian Federation
Russian Federation
Novosibirsk
References
1. Deloitte (2017). Russian pharmaceutical market trends in 2017. Track & trace system: Additional costs or opportunities? Moscow: Deloitte CIS Research Centre. https://www2.deloitte.com/content/dam/Deloitte/ru/Documents/life-sciences-health-care/russian-pharmaceutical-market-trends-2017-eng.pdf
2. Mokrousova I., Eremenko E. (2017). Kings of state procurement: Forbes rating. Forbes, March 2. (In Russian).
3. Mokrousova I., Eremenko E (2018). Kings of state procurement: Forbes rating. Forbes, February 22. (In Russian).
4. Moscow Exchange (2017). Overview of the global and Russian pharmaceutical market trends. (In Russian). https://fs.moex.com/files/14283
5. Osterwalder A., Pigneur Y. (2018). Building business models. Handbook of the strategist and innovator. Moscow: Alpina Publisher. (In Russian).
6. Deloitte (2018). Digital strategy: Building digital bridges to end consumers. Russian pharmaceutical market trends in 2018. Moscow: Deloitte CIS Research Centre. https://www2.deloitte.com/content/dam/Deloitte/ru/Documents/life-sciences-health-care/russian-pharmaceutical-market-trends-2018-en.pdf
7. DSM Group (2017). Russian pharmaceutical market 2017. Annual report. (In Russian). http://dsm.ru/docs/analytics/Annual_Report_2017_rus.pdf
8. DSM Group (2018). Фармацевтический рынок России 2018. Годовой отчет. [DSM Group (2018). Russian pharmaceutical market 2018. Annual report. (In Russian).] https://dsm.ru/docs/analytics/Annual_report_2018_DSM.pdf
9. Capo Fr., Brunetta F., Boccardelli P. (2014). Innovative business models in the pharmaceutical industry: A case on exploiting value networks to stay competitive. International Journal of Engineering Business Management. https://doi.org/10.5772/59155
10. Chesbrough H., Rosenbloom R. S. (2002). The role of the business model in capturing value from innovation: Evidence from Xerox corporation’s spin-off companies. Industrial and Corporate Change, Vol. 11, No. 3, pp. 529—555.
11. Ehrhardt M. (2015). Is pharma ready for the future? The way medicine is manufactured is about to be radically transformed. Strategy+Business, November 30. https://www.strategy-business.com/article/00363
12. Edmunds R., Pisani J., Strang D. (2016). Pharma’s identity crisis. Four strategies for creating value in life sciences. Strategy+Business, June 15. https://www.strategy-business.com/article/Pharmas-Identity-Crisis?gko=ac347IMAP (2016). Global M&A report. Pharma/biotech 2016. https://www.pharmablender.com/files/report/Global%20Pharma%20Biotech%20MA%20Report%202016.pdf
13. ITA (2016). 2016 top markets report pharmaceuticals. Washington, DC: International Trade Administration. https://www.trade.gov/topmarkets/pdf/Pharmaceuti-cals_Top_Markets_Reports.pdf
14. JSB Intelligence (2005). Strategic analysis of the pharma market, future revenue models and key players. http://www.fgcasal.org/politicafarmaceutica/docs/JSB_Intelligence.PDF
15. KPMG (2017). Pharma outlook 2030: From evolution to revolution. KPMG Global Strategy Group. https://assets.kpmg.com/content/dam/kpmg/xx/pdf/2017/02/pharma-outlook-2030-from-evolution-to-revolution.pdf
16. Magretta J. (2002). Why business models matter? Harvard Business Review, Vol. 80, р. 86-92.
17. Malone T. W., Weill P., Lai R. K., D’Urso V. T., Herman G., Apel Th. G., Woerner S. L. (2006). Do some business models perform better than others? Sloan School of Management, MIT Center for Coordination Science. MIT Sloan Research Paper, No. 4615-06.
18. Nielsen C., Lund M. (2014). An introduction to business models. In: C. Nielsen, M. Lund (eds.). The basics of business models. Copenhagen: BookBoon.com/Ventus Publishing Aps, pp. 8-20.
19. Osterwalder A., Pigneur Y., Tucci L. C. (2004). Clarifying business models: Origins, present, and future of the concept. Communications of AIS, Vol. 16, pp. 1-25.
20. Peruffo E., Pirolo L., Nenni M. E. (2014). Spin-off and innovation in the pharmaceutical industry. International Journal of Engineering Business Management. https://doi.org/10.5772/59019.
21. PhRMA (2015). 2015 biopharmaceutical research industry profile. Washington, DC: Pharmaceutical Research and Manufacturers of America. http://phrma-docs.phrma.org/sites/default/files/pdf/2015_phrma_profile.pdf
22. PricewaterhouseCoopers (2007). Pharma 2020: The vision. Which path will you take? https://www.pwc.com/gx/en/pharma-life-sciences/pdf/pharma2020final.pdf
23. Weill P., Malone T. W., D’Urso V. T., Herman G., Woerner S. L. (2004). Do some business models perform better than others? A study of the 1000 largest US firms. MIT Center for Coordination Science Working Paper, No. 226.
Review
For citations:
Kravchenko N.A., Yusupova A.T. Russian pharmaceutical companies: Business models of market leaders. Voprosy Ekonomiki. 2019;(8):127-138. (In Russ.) https://doi.org/10.32609/0042-8736-2019-8-127-138
Views:
1900
Email this article 
